Welzel Tania M, Miley Wendell J, Parks Thomas L, Goedert James J, Whitby Denise, Ortiz-Conde Betty A
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20892, USA.
J Clin Microbiol. 2006 Sep;44(9):3325-33. doi: 10.1128/JCM.00024-06.
The detection and quantification of hepatitis B virus (HBV) DNA play an important role in diagnosing and monitoring HBV infection as well as assessing therapeutic response. The great variability among HBV genotypes and the enormous range of clinical HBV DNA levels present challenges for PCR-based amplification techniques. In this study, we describe the development, evaluation, and validation of a novel real-time PCR assay designed to provide accurate quantification of DNA from all eight HBV genotypes in patient plasma specimens. A computer algorithm was used to design degenerate real-time PCR primers and probes based upon a large number (n = 340) of full-length genomic sequences including HBV genotypes A to H from Europe, Africa, Asia, and North and South America. Genotype performance was tested and confirmed using 59 genotype A to G specimens from two commercially available worldwide genotype panels. This assay has a dynamic range of at least 8 log(10) without the need for specimen dilution, good clinical intra- and interassay precision, and excellent correlation with the Bayer Diagnostics VERSANT HBV DNA 3.0 (branched DNA) assay (r = 0.93). Probit analysis determined the 95% detection level was 56 IU/ml, corresponding to 11 copies per PCR well. The high sensitivity, wide linear range, good reproducibility, and genotype inclusivity, combined with a small sample volume requirement and low cost, make this novel quantitative HBV real-time PCR assay particularly well suited for application to large clinical and epidemiological studies.
乙肝病毒(HBV)DNA的检测和定量在乙肝感染的诊断、监测以及评估治疗反应中发挥着重要作用。HBV基因型之间的巨大变异性以及临床HBV DNA水平的广泛范围给基于PCR的扩增技术带来了挑战。在本研究中,我们描述了一种新型实时PCR检测方法的开发、评估和验证,该方法旨在对患者血浆样本中所有八种HBV基因型的DNA进行准确定量。我们使用一种计算机算法,基于大量(n = 340)全长基因组序列设计简并实时PCR引物和探针,这些序列包括来自欧洲、非洲、亚洲以及南北美洲的A型至H型HBV基因型。使用来自两个市售全球基因型检测板的59个A型至G型基因型样本对基因型性能进行了测试和确认。该检测方法的动态范围至少为8个对数(10),无需样本稀释,具有良好的临床批内和批间精密度,并且与拜耳诊断公司的VERSANT HBV DNA 3.0(分支DNA)检测方法具有极好的相关性(r = 0.93)。概率分析确定95%检测水平为56 IU/ml,相当于每个PCR孔11个拷贝。这种新型定量HBV实时PCR检测方法具有高灵敏度、宽线性范围、良好的重复性和基因型包容性,再加上样本量需求小和成本低,特别适合应用于大型临床和流行病学研究。